Trial Outcomes & Findings for ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults (NCT NCT04856865)

NCT ID: NCT04856865

Last Updated: 2024-05-16

Results Overview

The proportion of participants in the pediatric ITT population who tolerated the 600mg level of a single qualifying food without dose limiting symptoms at the Week 40 Exit DBPCFC.

• Recruitment status: COMPLETED
• Study phase: PHASE1/PHASE2
• Target enrollment: 73 participants
• Primary outcome timeframe: 40 Weeks
• Results posted on: 2024-05-16

Participant Flow

Eligible participants were randomized in a 2:2:1:1 ratio to 1 of 4 arms, with 2 arms in each dosing regimen (low or high), to receive daily oral doses of study drug (either ADP101 or matching placebo) in a blinded fashion. Data from placebo participants (high-dose or low-dose) was analyzed in a pooled fashion (Pooled Placebo)

Participant milestones

Measure	Low Dose ADP101 Participants received ADP101 at a starting dose of 5mg po daily, with supervised updosing in the clinic as tolerated every 2 weeks to a target dose of 1500mg ADP101 over the 40 week treatment period. ADP101: Oral formulation mixture of 15 individual food sources from commercially available food flours containing allergenic proteins (almond, cashew, chicken's egg, codfish, cow's milk, hazelnut, peanut, pecan, pistachio, salmon, sesame seed, shrimp, soy, walnut, and wheat) with excipients. Each dose is formulated to contain equal parts by protein weight of each of the 15 individual foods in ADP101.	High Dose ADP101 Participants received ADP101 at a starting dose of 5mg po daily, with supervised updosing in the clinic as tolerated every 2 weeks to a target dose of 4500mg ADP101 over the 40 week treatment period. ADP101: Oral formulation mixture of 15 individual food sources from commercially available food flours containing allergenic proteins (almond, cashew, chicken's egg, codfish, cow's milk, hazelnut, peanut, pecan, pistachio, salmon, sesame seed, shrimp, soy, walnut, and wheat) with excipients. Each dose is formulated to contain equal parts by protein weight of each of the 15 individual foods in ADP101.	Pooled Placebo Participants received volume-matched placebo at a starting dose of 5mg po daily, with supervised updosing in the clinic as tolerated every 2 weeks to a target dose of 1500mg or 4500mg placebo over the 40 week treatment period. Placebo: Powder containing excipient, aroma and flavor maskers, and coloring agents to achieve similar appearance and total weight as the active, in the same cup packaging as the active.
Overall Study STARTED	25	24	24
Overall Study COMPLETED	19	16	21
Overall Study NOT COMPLETED	6	8	3

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Primary analysis population was the pediatric ITT population, age 4-17 years at the time of randomization

Baseline characteristics by cohort

Measure	Low Dose ADP101 n=25 Participants Participants received ADP101 at a starting dose of 5mg po daily, with supervised updosing in the clinic as tolerated every 2 weeks to a target dose of 1500mg ADP101 over the 40 week treatment period. ADP101: Oral formulation mixture of 15 individual food sources from commercially available food flours containing allergenic proteins (almond, cashew, chicken's egg, codfish, cow's milk, hazelnut, peanut, pecan, pistachio, salmon, sesame seed, shrimp, soy, walnut, and wheat) with excipients. Each dose is formulated to contain equal parts by protein weight of each of the 15 individual foods in ADP101.	High Dose ADP101 n=24 Participants Participants received ADP101 at a starting dose of 5mg po daily, with supervised updosing in the clinic as tolerated every 2 weeks to a target dose of 4500mg ADP101 over the 40 week treatment period. ADP101: Oral formulation mixture of 15 individual food sources from commercially available food flours containing allergenic proteins (almond, cashew, chicken's egg, codfish, cow's milk, hazelnut, peanut, pecan, pistachio, salmon, sesame seed, shrimp, soy, walnut, and wheat) with excipients. Each dose is formulated to contain equal parts by protein weight of each of the 15 individual foods in ADP101.	Pooled Placebo n=24 Participants Participants received volume-matched placebo at a starting dose of 5mg po daily, with supervised updosing in the clinic as tolerated every 2 weeks to a target dose of 1500mg or 4500mg placebo (see randomization scheme in pre-assignment details) over the 40 week treatment period. Placebo: Powder containing excipient, aroma and flavor maskers, and coloring agents to achieve similar appearance and total weight as the active, in the same cup packaging as the active.	Total n=73 Participants Total of all reporting groups
Age, Categorical <=18 years	21 Participants n=25 Participants	20 Participants n=24 Participants	20 Participants n=24 Participants	61 Participants n=73 Participants
Age, Categorical Between 18 and 65 years	4 Participants n=25 Participants	4 Participants n=24 Participants	4 Participants n=24 Participants	12 Participants n=73 Participants
Age, Categorical >=65 years	0 Participants n=25 Participants	0 Participants n=24 Participants	0 Participants n=24 Participants	0 Participants n=73 Participants
Age, Continuous	13.9 years STANDARD_DEVIATION 9.9 • n=25 Participants	12.1 years STANDARD_DEVIATION 6 • n=24 Participants	14.8 years STANDARD_DEVIATION 11.3 • n=24 Participants	13.6 years STANDARD_DEVIATION 9.3 • n=73 Participants
Age, Customized Mean (SD) age (years) of pediatric ITT population	10.3 years STANDARD_DEVIATION 3.4 • n=21 Participants • Primary analysis population was the pediatric ITT population, age 4-17 years at the time of randomization	9.9 years STANDARD_DEVIATION 2.8 • n=20 Participants • Primary analysis population was the pediatric ITT population, age 4-17 years at the time of randomization	10.1 years STANDARD_DEVIATION 3.5 • n=20 Participants • Primary analysis population was the pediatric ITT population, age 4-17 years at the time of randomization	10.1 years STANDARD_DEVIATION 3.2 • n=61 Participants • Primary analysis population was the pediatric ITT population, age 4-17 years at the time of randomization
Sex/Gender, Customized Gender · Female	7 Participants n=21 Participants • Primary analysis population was the pediatric ITT population, age 4-17 at the time of randomization	6 Participants n=20 Participants • Primary analysis population was the pediatric ITT population, age 4-17 at the time of randomization	7 Participants n=20 Participants • Primary analysis population was the pediatric ITT population, age 4-17 at the time of randomization	20 Participants n=61 Participants • Primary analysis population was the pediatric ITT population, age 4-17 at the time of randomization
Sex/Gender, Customized Gender · Male	14 Participants n=21 Participants • Primary analysis population was the pediatric ITT population, age 4-17 at the time of randomization	14 Participants n=20 Participants • Primary analysis population was the pediatric ITT population, age 4-17 at the time of randomization	13 Participants n=20 Participants • Primary analysis population was the pediatric ITT population, age 4-17 at the time of randomization	41 Participants n=61 Participants • Primary analysis population was the pediatric ITT population, age 4-17 at the time of randomization
Sex: Female, Male Female	10 Participants n=25 Participants	8 Participants n=24 Participants	11 Participants n=24 Participants	29 Participants n=73 Participants
Sex: Female, Male Male	15 Participants n=25 Participants	16 Participants n=24 Participants	13 Participants n=24 Participants	44 Participants n=73 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	1 Participants n=25 Participants	4 Participants n=24 Participants	0 Participants n=24 Participants	5 Participants n=73 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	23 Participants n=25 Participants	20 Participants n=24 Participants	22 Participants n=24 Participants	65 Participants n=73 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	1 Participants n=25 Participants	0 Participants n=24 Participants	2 Participants n=24 Participants	3 Participants n=73 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=25 Participants	0 Participants n=24 Participants	0 Participants n=24 Participants	0 Participants n=73 Participants
Race (NIH/OMB) Asian	6 Participants n=25 Participants	2 Participants n=24 Participants	5 Participants n=24 Participants	13 Participants n=73 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=25 Participants	0 Participants n=24 Participants	0 Participants n=24 Participants	0 Participants n=73 Participants
Race (NIH/OMB) Black or African American	0 Participants n=25 Participants	0 Participants n=24 Participants	3 Participants n=24 Participants	3 Participants n=73 Participants
Race (NIH/OMB) White	18 Participants n=25 Participants	20 Participants n=24 Participants	14 Participants n=24 Participants	52 Participants n=73 Participants
Race (NIH/OMB) More than one race	0 Participants n=25 Participants	0 Participants n=24 Participants	0 Participants n=24 Participants	0 Participants n=73 Participants
Race (NIH/OMB) Unknown or Not Reported	1 Participants n=25 Participants	2 Participants n=24 Participants	2 Participants n=24 Participants	5 Participants n=73 Participants
Region of Enrollment United States	25 Participants n=25 Participants	24 Participants n=24 Participants	24 Participants n=24 Participants	73 Participants n=73 Participants
Primary analysis population (pediatric ITT)	21 Participants n=25 Participants	20 Participants n=24 Participants	20 Participants n=24 Participants	61 Participants n=73 Participants

PRIMARY outcome

Timeframe: 40 Weeks

Population: The primary analysis population was the pediatric ITT population, age 4-17 years at the time of randomization

The proportion of participants in the pediatric ITT population who tolerated the 600mg level of a single qualifying food without dose limiting symptoms at the Week 40 Exit DBPCFC.

Outcome measures

Measure	Low Dose ADP101 n=21 Participants Participants received ADP101 at a starting dose of 5mg po daily, with supervised updosing in the clinic as tolerated every 2 weeks to a target dose of 1500mg ADP101 over the 40 week treatment period. ADP101:Oral formulation mixture of 15 individual food sources from commercially available food flours containing allergenic proteins (almond, cashew, chicken's egg, codfish, cow's milk, hazelnut, peanut, pecan, pistachio, salmon, sesame seed, shrimp, soy, walnut, and wheat) with excipients. Each dose is formulated to contain equal parts by protein weight of each of the 15 individual foods in ADP101.	High Dose ADP101 n=20 Participants Participants received ADP101 at a starting dose of 5mg po daily, with supervised updosing in the clinic as tolerated every 2 weeks to a target dose of 4500mg ADP101 over the 40 week treatment period. ADP101:Oral formulation mixture of 15 individual food sources from commercially available food flours containing allergenic proteins (almond, cashew, chicken's egg, codfish, cow's milk, hazelnut, peanut, pecan, pistachio, salmon, sesame seed, shrimp, soy, walnut, and wheat) with excipients. Each dose is formulated to contain equal parts by protein weight of each of the 15 individual foods in ADP101.	Pooled Placebo n=20 Participants Participants received volume-matched placebo at a starting dose of 5mg po daily, with supervised updosing in the clinic as tolerated every 2 weeks to a target dose of 1500mg or 4500mg placebo over the 40 week treatment period. Placebo:Powder containing excipient, aroma and flavor maskers, and coloring agents to achieve similar appearance and total weight as the active, in the same cup packaging as the active.
600mg Desensitization in at Least One Qualifying Food	8 Participants	11 Participants	4 Participants

SECONDARY outcome

Timeframe: 40 weeks

Population: Primary analysis population was the pediatric ITT population, age 4-17 years at the time of randomization

Proportion of participants in the pediatric ITT population (age 4-17 at randomization) who tolerated the 1000mg level of a single qualifying food without dose limiting symptoms at the Week 40 Exit DBPCFC.

Outcome measures

Measure	Low Dose ADP101 n=21 Participants Participants received ADP101 at a starting dose of 5mg po daily, with supervised updosing in the clinic as tolerated every 2 weeks to a target dose of 1500mg ADP101 over the 40 week treatment period. ADP101:Oral formulation mixture of 15 individual food sources from commercially available food flours containing allergenic proteins (almond, cashew, chicken's egg, codfish, cow's milk, hazelnut, peanut, pecan, pistachio, salmon, sesame seed, shrimp, soy, walnut, and wheat) with excipients. Each dose is formulated to contain equal parts by protein weight of each of the 15 individual foods in ADP101.	High Dose ADP101 n=20 Participants Participants received ADP101 at a starting dose of 5mg po daily, with supervised updosing in the clinic as tolerated every 2 weeks to a target dose of 4500mg ADP101 over the 40 week treatment period. ADP101:Oral formulation mixture of 15 individual food sources from commercially available food flours containing allergenic proteins (almond, cashew, chicken's egg, codfish, cow's milk, hazelnut, peanut, pecan, pistachio, salmon, sesame seed, shrimp, soy, walnut, and wheat) with excipients. Each dose is formulated to contain equal parts by protein weight of each of the 15 individual foods in ADP101.	Pooled Placebo n=20 Participants Participants received volume-matched placebo at a starting dose of 5mg po daily, with supervised updosing in the clinic as tolerated every 2 weeks to a target dose of 1500mg or 4500mg placebo over the 40 week treatment period. Placebo:Powder containing excipient, aroma and flavor maskers, and coloring agents to achieve similar appearance and total weight as the active, in the same cup packaging as the active.
1000mg Desensitization Threshold in Pediatric ITT Population	5 Participants	10 Participants	3 Participants

SECONDARY outcome

Timeframe: 40 weeks

Population: Primary analysis population is the pediatric ITT population age 4-17 years at the time of randomization

Proportion of participants with >=2 qualifying FAs in the pediatric ITT population (age 4-17 at randomization) who tolerated the 600mg level of each of 2 or more qualifying foods without dose limiting symptoms at the Week 40 Exit DBPCFC.

Outcome measures

Measure	Low Dose ADP101 n=21 Participants Participants received ADP101 at a starting dose of 5mg po daily, with supervised updosing in the clinic as tolerated every 2 weeks to a target dose of 1500mg ADP101 over the 40 week treatment period. ADP101:Oral formulation mixture of 15 individual food sources from commercially available food flours containing allergenic proteins (almond, cashew, chicken's egg, codfish, cow's milk, hazelnut, peanut, pecan, pistachio, salmon, sesame seed, shrimp, soy, walnut, and wheat) with excipients. Each dose is formulated to contain equal parts by protein weight of each of the 15 individual foods in ADP101.	High Dose ADP101 n=20 Participants Participants received ADP101 at a starting dose of 5mg po daily, with supervised updosing in the clinic as tolerated every 2 weeks to a target dose of 4500mg ADP101 over the 40 week treatment period. ADP101:Oral formulation mixture of 15 individual food sources from commercially available food flours containing allergenic proteins (almond, cashew, chicken's egg, codfish, cow's milk, hazelnut, peanut, pecan, pistachio, salmon, sesame seed, shrimp, soy, walnut, and wheat) with excipients. Each dose is formulated to contain equal parts by protein weight of each of the 15 individual foods in ADP101.	Pooled Placebo n=20 Participants Participants received volume-matched placebo at a starting dose of 5mg po daily, with supervised updosing in the clinic as tolerated every 2 weeks to a target dose of 1500mg or 4500mg placebo over the 40 week treatment period. Placebo:Powder containing excipient, aroma and flavor maskers, and coloring agents to achieve similar appearance and total weight as the active, in the same cup packaging as the active.
600mg Desensitization Threshold, Multi-allergic Pediatric ITT Population	2 Participants	5 Participants	0 Participants

SECONDARY outcome

Timeframe: 40 Weeks

Population: The primary analysis population is the pediatric ITT population, age 4-17 years at the time of randomization

Proportion of participants with >=2 qualifying FAs in the pediatric ITT population (age 4-17 at randomization) who tolerated the 1000mg level of each of 2 or more qualifying foods without dose limiting symptoms at the Week 40 Exit DBPCFC.

Outcome measures

Measure	Low Dose ADP101 n=21 Participants Participants received ADP101 at a starting dose of 5mg po daily, with supervised updosing in the clinic as tolerated every 2 weeks to a target dose of 1500mg ADP101 over the 40 week treatment period. ADP101:Oral formulation mixture of 15 individual food sources from commercially available food flours containing allergenic proteins (almond, cashew, chicken's egg, codfish, cow's milk, hazelnut, peanut, pecan, pistachio, salmon, sesame seed, shrimp, soy, walnut, and wheat) with excipients. Each dose is formulated to contain equal parts by protein weight of each of the 15 individual foods in ADP101.	High Dose ADP101 n=20 Participants Participants received ADP101 at a starting dose of 5mg po daily, with supervised updosing in the clinic as tolerated every 2 weeks to a target dose of 4500mg ADP101 over the 40 week treatment period. ADP101:Oral formulation mixture of 15 individual food sources from commercially available food flours containing allergenic proteins (almond, cashew, chicken's egg, codfish, cow's milk, hazelnut, peanut, pecan, pistachio, salmon, sesame seed, shrimp, soy, walnut, and wheat) with excipients. Each dose is formulated to contain equal parts by protein weight of each of the 15 individual foods in ADP101.	Pooled Placebo n=20 Participants Participants received volume-matched placebo at a starting dose of 5mg po daily, with supervised updosing in the clinic as tolerated every 2 weeks to a target dose of 1500mg or 4500mg placebo over the 40 week treatment period. Placebo:Powder containing excipient, aroma and flavor maskers, and coloring agents to achieve similar appearance and total weight as the active, in the same cup packaging as the active.
1000mg Desensitization Threshold, Multi-allergic Pediatric ITT Population	1 Participants	4 Participants	0 Participants

Adverse Events

Low Dose ADP101, Pediatric Safety Population

Serious events: 0 serious events

Other events: 20 other events

Deaths: 0 deaths

High Dose ADP101, Pediatric Safety Population

Serious events: 1 serious events

Other events: 19 other events

Deaths: 0 deaths

Pooled PBO, Pediatric Safety Population

Serious events: 0 serious events

Other events: 19 other events

Deaths: 0 deaths

Low Dose ADP101, All-participants Safety Population

Serious events: 0 serious events

Other events: 24 other events

Deaths: 0 deaths

High Dose ADP101, All-participants Safety Population

Serious events: 1 serious events

Other events: 23 other events

Deaths: 0 deaths

Pooled PBO, All-participants Safety Population

Serious events: 0 serious events

Other events: 23 other events

Deaths: 0 deaths

Serious adverse events

Measure	Low Dose ADP101, Pediatric Safety Population n=21 participants at risk Participants received ADP101 at a starting dose of 5mg po daily, with supervised updosing in the clinic as tolerated every 2 weeks to a target dose of 1500mg ADP101 over the 40 week treatment period.	High Dose ADP101, Pediatric Safety Population n=20 participants at risk Participants received ADP101 at a starting dose of 5mg po daily, with supervised updosing in the clinic as tolerated every 2 weeks to a target dose of 4500mg ADP101 over the 40 week treatment period.	Pooled PBO, Pediatric Safety Population n=20 participants at risk Participants received volume-matched placebo at a starting dose of 5mg po daily, with supervised updosing in the clinic as tolerated every 2 weeks to a target dose of 1500mg or 4500mg placebo over the 40 week treatment period.	Low Dose ADP101, All-participants Safety Population n=25 participants at risk Participants received ADP101 at a starting dose of 5mg po daily, with supervised updosing in the clinic as tolerated every 2 weeks to a target dose of 1500mg ADP101 over the 40 week treatment period.	High Dose ADP101, All-participants Safety Population n=24 participants at risk Participants received ADP101 at a starting dose of 5mg po daily, with supervised updosing in the clinic as tolerated every 2 weeks to a target dose of 4500mg ADP101 over the 40 week treatment period.	Pooled PBO, All-participants Safety Population n=24 participants at risk Participants received volume-matched placebo at a starting dose of 5mg po daily, with supervised updosing in the clinic as tolerated every 2 weeks to a target dose of 1500mg or 4500mg placebo over the 40 week treatment period.
Immune system disorders Anaphylaxis	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Number of events 1 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Number of events 1 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.

Other adverse events

Measure	Low Dose ADP101, Pediatric Safety Population n=21 participants at risk Participants received ADP101 at a starting dose of 5mg po daily, with supervised updosing in the clinic as tolerated every 2 weeks to a target dose of 1500mg ADP101 over the 40 week treatment period.	High Dose ADP101, Pediatric Safety Population n=20 participants at risk Participants received ADP101 at a starting dose of 5mg po daily, with supervised updosing in the clinic as tolerated every 2 weeks to a target dose of 4500mg ADP101 over the 40 week treatment period.	Pooled PBO, Pediatric Safety Population n=20 participants at risk Participants received volume-matched placebo at a starting dose of 5mg po daily, with supervised updosing in the clinic as tolerated every 2 weeks to a target dose of 1500mg or 4500mg placebo over the 40 week treatment period.	Low Dose ADP101, All-participants Safety Population n=25 participants at risk Participants received ADP101 at a starting dose of 5mg po daily, with supervised updosing in the clinic as tolerated every 2 weeks to a target dose of 1500mg ADP101 over the 40 week treatment period.	High Dose ADP101, All-participants Safety Population n=24 participants at risk Participants received ADP101 at a starting dose of 5mg po daily, with supervised updosing in the clinic as tolerated every 2 weeks to a target dose of 4500mg ADP101 over the 40 week treatment period.	Pooled PBO, All-participants Safety Population n=24 participants at risk Participants received volume-matched placebo at a starting dose of 5mg po daily, with supervised updosing in the clinic as tolerated every 2 weeks to a target dose of 1500mg or 4500mg placebo over the 40 week treatment period.
Gastrointestinal disorders Abdominal pain	47.6% 10/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	30.0% 6/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	30.0% 6/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	44.0% 11/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	25.0% 6/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	33.3% 8/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Gastrointestinal disorders Nausea	42.9% 9/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	35.0% 7/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	10.0% 2/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	48.0% 12/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	33.3% 8/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	16.7% 4/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Gastrointestinal disorders Oral pruritis	23.8% 5/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	35.0% 7/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	25.0% 5/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	36.0% 9/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	33.3% 8/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	29.2% 7/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Gastrointestinal disorders Abdominal pain upper	19.0% 4/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	35.0% 7/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	20.0% 4/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	20.0% 5/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	37.5% 9/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	25.0% 6/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Gastrointestinal disorders Vomiting	28.6% 6/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	25.0% 5/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	20.0% 4/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	28.0% 7/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	29.2% 7/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	16.7% 4/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Gastrointestinal disorders Diarrhoea	23.8% 5/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	35.0% 7/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	20.0% 5/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	8.3% 2/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	37.5% 9/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Gastrointestinal disorders Paresthesia oral	38.1% 8/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	10.0% 2/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	10.0% 2/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	32.0% 8/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	8.3% 2/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	20.8% 5/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Gastrointestinal disorders Abdominal discomfort	23.8% 5/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	20.0% 4/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	20.0% 5/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	25.0% 6/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	8.3% 2/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Gastrointestinal disorders Tongue pruritis	19.0% 4/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	10.0% 2/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	16.0% 4/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	8.3% 2/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Gastrointestinal disorders Lip swelling	14.3% 3/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	10.0% 2/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	12.0% 3/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	8.3% 2/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Gastrointestinal disorders Dyspepsia	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Gastrointestinal disorders Dysphagia	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	10.0% 2/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.0% 1/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	8.3% 2/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Gastrointestinal disorders Gastroesophageal reflux disease	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Gastrointestinal disorders Hypoaesthesia oral	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	10.0% 2/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	8.3% 2/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Gastrointestinal disorders Lip erythema	4.8% 1/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.0% 1/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Gastrointestinal disorders Lip pruritis	4.8% 1/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.0% 1/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	8.3% 2/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Gastrointestinal disorders Salivary hypersecretion	4.8% 1/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.0% 1/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Gastrointestinal disorders Constipation	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Gastrointestinal disorders Dental caries	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Gastrointestinal disorders Flatulence	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Gastrointestinal disorders Lip oedema	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Gastrointestinal disorders Oral discomfort	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.0% 1/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Gastrointestinal disorders Retching	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders Nasal congestion	33.3% 7/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	35.0% 7/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	10.0% 2/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	32.0% 8/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	29.2% 7/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	12.5% 3/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders Cough	28.6% 6/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	15.0% 3/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	25.0% 5/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	32.0% 8/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	16.7% 4/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	25.0% 6/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders Throat irritation	23.8% 5/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	20.0% 4/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	25.0% 5/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	20.0% 5/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	25.0% 6/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	29.2% 7/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders Rhinorrhea	19.0% 4/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	15.0% 3/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	10.0% 2/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	20.0% 5/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	12.5% 3/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	12.5% 3/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	19.0% 4/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	10.0% 2/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	16.0% 4/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	12.5% 3/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders Sneezing	9.5% 2/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	15.0% 3/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	8.0% 2/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	12.5% 3/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	8.3% 2/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders Throat tightness	4.8% 1/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	15.0% 3/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	10.0% 2/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	8.0% 2/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	12.5% 3/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	12.5% 3/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders Dyspnoea	4.8% 1/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	15.0% 3/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	8.0% 2/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	12.5% 3/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders Pharyngeal paraesthesia	9.5% 2/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	8.0% 2/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders Wheezing	9.5% 2/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	8.0% 2/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders Nasal pruritis	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	10.0% 2/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	8.3% 2/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	8.3% 2/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders Oropharyngeal discomfort	4.8% 1/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.0% 1/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders Throat clearing	4.8% 1/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	10.0% 2/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	8.0% 2/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	8.3% 2/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders Dysphonia	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	12.5% 3/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders Asthma exercise induced	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders Pharyngeal swelling	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders Rhinitis allergic	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Respiratory, thoracic and mediastinal disorders Upper-airway cough syndrome	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Infections and infestations COVID-19	28.6% 6/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	35.0% 7/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	30.0% 6/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	32.0% 8/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	37.5% 9/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	25.0% 6/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Infections and infestations Upper respiratory tract infection	19.0% 4/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	25.0% 5/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	10.0% 2/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	20.0% 5/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	25.0% 6/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	12.5% 3/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Infections and infestations Viral infection	9.5% 2/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	15.0% 3/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	15.0% 3/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	8.0% 2/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	12.5% 3/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	12.5% 3/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Infections and infestations Gastroenteritis viral	14.3% 3/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	10.0% 2/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	10.0% 2/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	12.0% 3/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	8.3% 2/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	8.3% 2/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Infections and infestations Nasopharyngitis	9.5% 2/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	20.0% 4/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	8.0% 2/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	16.7% 4/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Infections and infestations Ear infection	4.8% 1/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.0% 1/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Infections and infestations Influenza	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Infections and infestations Otitis media	4.8% 1/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.0% 1/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	8.3% 2/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Infections and infestations Croup infectious	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Infections and infestations Gastroenteritis	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Infections and infestations Gastroenteritis norovirus	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Infections and infestations Laryngitis viral	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Infections and infestations Otitis media acute	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Infections and infestations Pulpitis dental	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Infections and infestations Viral upper respiratory tract infection	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Skin and subcutaneous tissue disorders Urticaria	33.3% 7/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	30.0% 6/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	35.0% 7/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	36.0% 9/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	29.2% 7/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	29.2% 7/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Skin and subcutaneous tissue disorders Pruritis	33.3% 7/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	25.0% 5/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	15.0% 3/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	32.0% 8/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	20.8% 5/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	25.0% 6/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Skin and subcutaneous tissue disorders Erythema	14.3% 3/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	10.0% 2/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	20.0% 4/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	12.0% 3/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	8.3% 2/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	16.7% 4/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Skin and subcutaneous tissue disorders Rash	4.8% 1/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	15.0% 3/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	12.0% 3/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	12.5% 3/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Skin and subcutaneous tissue disorders Angioedema	4.8% 1/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	15.0% 3/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.0% 1/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	20.8% 5/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Skin and subcutaneous tissue disorders Acne	4.8% 1/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.0% 1/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Skin and subcutaneous tissue disorders Dermatitis acneiform	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Skin and subcutaneous tissue disorders Ecchymosis	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Skin and subcutaneous tissue disorders Granuloma annulare	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Skin and subcutaneous tissue disorders Perioral dermatitis	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Skin and subcutaneous tissue disorders Rash macular	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.0% 1/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Immune system disorders Anaphylactic reaction	38.1% 8/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	45.0% 9/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	55.0% 11/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	40.0% 10/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	45.8% 11/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	54.2% 13/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Immune system disorders Hypersensitivity	4.8% 1/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.0% 1/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Immune system disorders Seasonal allergy	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	10.0% 2/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	8.3% 2/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Immune system disorders Food allergy	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Nervous system disorders Headache	23.8% 5/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	15.0% 3/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	20.0% 5/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	16.7% 4/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Nervous system disorders Dizziness	4.8% 1/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.0% 1/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Nervous system disorders Lethargy	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	10.0% 2/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	8.3% 2/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Nervous system disorders Paraesthesia	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Nervous system disorders Syncope	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
General disorders Chest discomfort	9.5% 2/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	12.0% 3/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	8.3% 2/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
General disorders Pyrexia	4.8% 1/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	10.0% 2/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.0% 1/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	12.5% 3/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
General disorders Fatigue	9.5% 2/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	8.0% 2/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
General disorders Chills	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
General disorders Feeling abnormal	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
General disorders Swelling face	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Injury, poisoning and procedural complications Arthropod sting	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	10.0% 2/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	8.3% 2/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Injury, poisoning and procedural complications Vaccination complication	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.0% 1/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Injury, poisoning and procedural complications Accidental exposure to product	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.0% 1/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Injury, poisoning and procedural complications Contusion	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Injury, poisoning and procedural complications Scratch	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Injury, poisoning and procedural complications Skin laceration	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Injury, poisoning and procedural complications Sunburn	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Eye disorders Eye pruritis	9.5% 2/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	15.0% 3/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	8.0% 2/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	12.5% 3/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Eye disorders Conjunctivitis allergic	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	10.0% 2/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	8.3% 2/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Eye disorders Ocular hyperaemia	4.8% 1/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.0% 1/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Eye disorders Eye swelling	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Eye disorders Lacrimation increased	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Ear and labyrinth disorders Ear pain	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	10.0% 2/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	8.3% 2/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Ear and labyrinth disorders Ear pruritis	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	10.0% 2/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	8.3% 2/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Ear and labyrinth disorders Tinnitus	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Vascular disorders Flushing	4.8% 1/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.0% 1/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Vascular disorders Pallor	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Skin papilloma	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Psychiatric disorders Anxiety	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Psychiatric disorders Attention deficit hyperactivity disorder	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Psychiatric disorders Irritability	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Reproductive system and breast disorders Dysmenorrhea	4.8% 1/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.0% 1/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort	0.00% 0/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	5.0% 1/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.2% 1/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.
Gastrointestinal disorders Eosinophilic oesophagitis	4.8% 1/21 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/20 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	4.0% 1/25 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.	0.00% 0/24 • Adverse Events (AEs) were collected from consent until 14 days after last dose of study drug, up to approximately 52 weeks of treatment. Serious adverse events (SAEs) considered related to ADP101 were to be reported at any time until resolution/stabilization of the SAE. Allergic reactions were graded according to the Consortium of Food Allergy Research (CoFAR grading system, Jones et al. 2017),including events that met the definition for anaphylaxis. The pediatric Safety population included all pediatric participants (age 4-17 at the time of randomization) who received at least one dose of study drug. The All-participants safety population included all participants (age 4-55 years at the time of randomization) who received at least one dose of study drug.

Additional Information

Chief Medical Officer

Alladapt Immunotherapeutics

Phone: 650-420-3900

Email: info@alladapt.com

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place